ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301
| EMCCX Fund | USD 57.09 0.55 0.97% |
Slightly above 51% of Empiric 2500's investor base is interested to short. The analysis of overall sentiment of trading Empiric 2500 Fund mutual fund suggests that many investors are impartial at this time. Empiric 2500's investing sentiment can be driven by a variety of factors including economic data, Empiric 2500's earnings reports, geopolitical events, and overall market trends.
Empiric |
Safety, pharmacokinetics and target engagement data from first-in-human Phase 1 clinical trial in healthy volunteers will potentially enable rapid advancement of IMSB301 into Phase 1b2 clinical studies in Type I interferonopathiesDALLAS, Oct. 08, 2024 -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of first- and best-in-class inhibitors and agonists targeting the cGAS-STING pathway to address diverse peripheral and CNS indicatio
Read at finance.yahoo.com
 |
Empiric 2500 Fundamental Analysis
We analyze Empiric 2500's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Empiric 2500 using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Empiric 2500 based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Empiric 2500 is currently under evaluation in net asset among similar funds. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Empiric 2500 Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Empiric 2500 mutual fund to make a market-neutral strategy. Peer analysis of Empiric 2500 could also be used in its relative valuation, which is a method of valuing Empiric 2500 by comparing valuation metrics with similar companies.
Peers
Empiric 2500 Related Equities
| ABIMX | Ab Impact | 0.31 | ||||
| CFNLX | National Tax | 0.22 | ||||
| TIMTX | Transamerica Intermediate | 0.19 | ||||
| OWMBX | Old Westbury | 0.18 | ||||
| PRFHX | T Rowe | 0.09 |
Other Information on Investing in Empiric Mutual Fund
Empiric 2500 financial ratios help investors to determine whether Empiric Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Empiric with respect to the benefits of owning Empiric 2500 security.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |